Prof Denis Migliorini (Geneva University Hospitals, Geneva, Switzerland) to discuss his presentation at the ESMO Immuno-Oncology Congress 2021 on the challenges of developing CAR-T therapies for brain tumours, and the future of this treatment in clinical practice.
Questions
1. What molecules have been identified as targets for CAR-T cell therapy in glioblastoma? 00:13-04:21
2. What clinical trials are currently ongoing/completed and what have been their findings? 04:21-06:28
3. What future studies are planned? 06:28-08:20
Speaker Disclosure: Denis Migliorini has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO Immuno-Oncology Congress 2021
